Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3335-3344

  Hofstra, L S ^a   Kristensen, G B ^a   Willemse, P H ^a   Vindevoghel, A ^a   Meden, H ^a   Lahousen, M ^a   Oberling, F ^a   Sorbe, B ^a   Crump, M ^a   Sklenar, I ^a   Sluiter, W J ^a   Kiese, B ^a   Trope, C G ^a   de Vries, E G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; PARACETAMOL; RECOMBINANT INTERLEUKIN 3;

ADULT; AGED; ALLERGY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEADACHE; HEMATOPOIESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031727310     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3335     Document Type: Article

References (43)

1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
2. Gruppo Interegionale Cooperativo Oncologico Ginecologia: Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/ cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987
3. Hainsworth JD, Grosh WW, Burnett LS, et al: Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 108:176-180, 1988
4. Neijt JP, Ten Bokkel Huinink WW, Van der Burg ME, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987
5. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide; Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
6. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10:718-726, 1992
7. Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 303:884-893, 1991
8. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant granulocyte-macrophage colony-stimulating factor on chemotherapy induced myelosuppression. N Engl J Med 319:593-598, 1988.
9. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869-876, 1988
10. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
11. Sheridan WP, Wolf M, Lusk J, et al: Granulocyte-colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891-895, 1989
12. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871-877, 1990
13. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
14. Edmonson JH, Long HJ, Jeffries JA, et al: Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: Apparent dose and schedule dependency. J Natl Cancer Inst 81:1510-1512, 1989
15. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
16. De Vries EGE, Biesma B, Willemse PHB, et al: A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51:116-122, 1991
17. Leary AG, Yang Y-C, Clark SC, et al: Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 70:1343-1348, 1987
18. Sonoda Y, Chang Y-C, Wong GG, et al: Analysis in serum-free culture of the targets of recombinant human hematopoietic growth factors: Interleukin 3 and granulocyte/macrophage-colony-stimulating factor are specific for early developmental stages. Proc Natl Acad Sci USA 85:4360-4364, 1988
19. Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666-676, 1990
20. Ganser A, Seipelt G, Lindemann A, et al: Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455-462, 1990
21. Ganser A, Lindemann A, Seipelt G, et al: Effects of recombinant human interleukin-3 in aplastic anaemia. Blood 76:1287-1292, 1990
22. Kurzrock R, Talpaz M, Estrov Z, et al: Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241-1250, 1991
23. Postmus PE, Gietema JA, Damsma O, et al: Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: A dose finding study. J Clin Oncol 10:1131-1140, 1992
24. Biesma B, Willemse PHB, Mulder NH, et al: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80:1141-1148, 1992
25. Veldhuis GJ, Willemse PHB, Van Gameren MM, et al: Recombinant human interleukin-3 to dose intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer. J Clin Oncol 13:733-740, 1995
26. Speyer JL, Mandeli J, Hochster H, et al: A phase I trial of cyclophosphamide and carboplatinum combined with interleukin-3 in woman with advanced stage ovarian cancer. Gynecol Oncol 56:387-394, 1995
27. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989.
28. Morandi MM, Carson LF, Weinberg B, et al: Serum and ascites fluid levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with ovarian epithelian cancer. Cancer 72:2433-2440, 1993
29. D'Hondt V, Weynants P, Humblet Y, et al: Dose dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11:2063-2071, 1993
30. Bukowski RM, Olencki T, Gunn H, et al: Phase I trial of subcutaneous interleukin-3 in patients with refractory malignancy: Haematological, immunological and pharmacodynamic findings. Clin Cancer Res 2:347-357, 1996
31. O'Shaughnessy JA, Tolcher A, Riseberg D, et al: Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/ granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 87:2205-2211, 1996
32. Kay AB, Ying S, Varney V, et al: Messenger RNA expression of the cytokine gene cluster, interleukin-3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony stimulating factor, in allergen induced late phase cutaneous reactions in atopic subjects. J Exp Med 173:775-778, 1991
33. 2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326:298-304, 1992
34. Walker C, Virchow JC, Bruijnzeel PL, et al: T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 146:1829-1835, 1991
35. Matsumoto T: Ongoing IgE synthesis by atopic B cells is enhanced by interleukin-3 and suppressed directly by interferon-gamma in vivo. Int Arch Allergy Appl Immunol 95:48-52, 1991
36. MacDonald SM, Schleimer RP, Kagey-Sobotka A, et al: Recombinant IL-3 induces histamine release in human basophils. J Immunol 142:3527-3532, 1989
37. Alam R, Weltyer JB, Forsythe PA, et al: Comparative effect of recombinant IL-1, -2, -3, -4, and -6, IFN-gamma, granulocyte-macrophage colony stimulating factor, tumour necrosis factor-alpha and histamine-releasing factors on the secretion of histamine from basophils. J Immunol 142:3431-3435, 1989
38. Mayer P, Valent P, Schmidt G, et al: The in vivo effects of recombinant human interleukin-3: Demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood 74:613-621, 1989
39. Sugiyama H, Eda R, Hopp RJ, et al: Importance of interleukin-3 on histamine release from human basophils. Ann Allergy 71:391-395, 1993
40. Rothenberg ME, Owen WF, Silberstein DS, et al: Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3. J Clin Invest 81:1986-1992, 1988
41. Yamaguchi M, Hirai K, Ohta K, et al: Nonreleasing basophils convert to releasing basophils by culturing with IL-3. J Allergy Clin Immunol 97:1279-1287, 1996
42. Dercksen MW, Hoekman K, Visser JJ, et al: Hypotension induced by interleukin-3 in patients on angiotensin-converting-enzyme inhibitors. Lancet 345:448, 1995 (letter)
43. Wielenga JJ, Vellenga E, Groenewegen A, et al: Recombinant human interleukin-3 (rHIL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): A phase I/II study. Leukemia 10:43-47, 1996